Portfolio company
Vitarka
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
Vitarka develops intracellular drug delivery technology for RNA therapeutics to treat solid tumours in humans and address animal health challenges in agriculture.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Kodikaz Therapeutic Solutions
This deep-tech company develops a non-viral delivery platform for cell-specific gene therapies to treat cancer patients.
SymphoRNA
This deep-tech company develops multi-RNA combination medicines to treat complex diseases such as fibrosis and heart failure for the pharmaceutical and healthcare sectors.
ParcelBio
This deep-tech firm develops mRNA delivery technologies and programmable medicines for biotechnology and pharmaceutical organisations to treat autoimmune diseases and oncology.
EditForce
This deep-tech firm develops RNA editing tools and therapies for pharmaceutical, industrial, and agricultural organisations to treat diseases and manipulate genes.
Synthetic biology-powered mRNA therapeutics
The company develops programmable mRNA therapies using synthetic biology genetic circuits to deliver precise treatments for patients with cancer and other complex diseases.
Kerna
This company develops an artificial intelligence platform to design and deliver messenger ribonucleic acid medicines for patients with previously untreatable conditions.
Breeze
This company develops polymer nanoparticles to enable the non-viral delivery of RNA therapeutics to extrahepatic tissues for biotechnology and pharmaceutical organisations.
Vitra Labs
The company develops a stem cell platform to produce eggs for patients undergoing fertility treatments without the use of hormones or donor tissue.
